FGA fibrinogen alpha chain
ENSG00000171560 · protein coding · Open Targets profile
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re- epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Pocket
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Half-life Data
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.9865700006484985 (upper bound 1.4335999488830566). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 156 registry trials, updated in the last three years, of the most advanced drugs against FGA (ancrod, fibrinolysin, human, plasminogen, alfimeprase), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Craig AndersonThe George Institute · 4 of 4 trials Phase 2+
- Raul G NogueiraUniversity of Pittsburgh · 3 of 4 trials Phase 2+
- Bijoy K MenonUniversity of Calgary · 3 of 3 trials Phase 2+
- Yamei TangSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 3 of 3 trials Phase 2+
- Yongjun WangBeijing Tiantan Hospital · 3 of 3 trials Phase 2+
- Yunyun XiongBeijing Tiantan Hospital · 3 of 3 trials Phase 2+Ph3NCT07047014 · Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Strokebrief
- Yong CaoBeijing Tiantan Hospital · 2 of 3 trials Phase 2+
- Bo SongDepartment of Neurology, the First Affiliated Hospital of Zhengzhou University · 2 of 2 trials Phase 2+
- Bruce CampbellUniversity of Melbourne · 2 of 2 trials Phase 2+
- Fana AlemsegedUniversity of Melbourne · 2 of 2 trials Phase 2+
- Junwei HaoXuanwu Hospital, Beijing · 2 of 2 trials Phase 2+
- Michael D HillUniversity of Calgary · 2 of 2 trials Phase 2+
- mohamed G. Zeinhomneurology department kafr el-sheikh university · 2 of 2 trials Phase 2+
- Oksana A. MarkovaAO GENERIUM · 2 of 2 trials Phase 2+
- Sergey S MarkinSupergene, LLC · 2 of 2 trials Phase 2+
Registry trials of ancrod, fibrinolysin, human, plasminogen, alfimeprase updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 125 of 150 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 6 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
83 trials of drugs against FGA were stopped early; 10 give no reason
Terminated, withdrawn and suspended interventional trials of ancrod, fibrinolysin, human, plasminogen, alfimeprase, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 83.
- terminated · 2026-09-25 · Northwestern University · matched by the registry's drug synonyms“Enrollment challenges due to decline in COVID”
- terminated · 2026-06-01 · Vanderbilt University · matched by the registry's drug synonyms“poor enrollment”
- terminated · 2026-05-18 · University Hospital Tuebingen · matched by the registry's drug synonyms“Stopped after prespecified interim analysis due to futility”
- withdrawn · 2026-04-29 · Centre hospitalier de l'Université de Montréal (CHUM) · matched by the registry's drug synonyms“Change for a phase II design”
- terminated · 2026-04-14 · Kaiser Permanente · matched by the registry's drug synonyms“Unable to accrue patients at a reasonable rate”
- terminated · 2025-07-25 · University Hospital, Caen · matched by the registry's drug synonyms“lack of patient”
- terminated · 2025-07-02 · General Hospital of Shenyang Military Region · matched by the registry's drug synonyms“The interim analysis showed the potential harm of intra-arterial TNK.”
- terminated · 2025-06-15 · PlasFree Ltd. · matched by the registry's drug synonyms“The study was stopped to evaluate the differences between the indications.”
- terminated · 2025-03-03 · Haukeland University Hospital · matched by the registry's drug synonyms“Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups.”
- terminated · 2025-01-15 · University of Melbourne · matched by the registry's drug synonyms“Loss of equipoise in the 0-4.5h population which comprised the majority of ETERNAL-LVO trial recruitment due to publication of other trials demonstrating efficacy of tenecteplase vs alteplase in the 0-4.5h time window.”
- withdrawn · 2024-10-16 · Wake Forest University Health Sciences · matched by the registry's drug synonyms“drug has expired, no enrollments in study. Company pulled funding”
- withdrawn · 2024-10-01 · ZZ Biotech, LLC · matched by the registry's drug synonyms“NIH funding suspension.”
- terminated · 2024-08-23 · Chiesi Farmaceutici S.p.A. · matched by the registry's drug synonyms“Due to ongoing recruitment challenges globally, it is not possible to complete this study. The decision is not based on any reported changes in the safety profile or any concerns with the anticipated efficacy profile of the investigational product.”
- terminated · 2024-06-26 · NYU Langone Health · matched by the registry's drug synonyms“Both lack of enrollment as well as study staff turnover”
- withdrawn · 2024-02-08 · Azienda U.S.L. 1 di Massa e Carrara · matched by the registry's drug synonymsNo reason given
- terminated · 2023-12-05 · University Hospital Heidelberg · matched by the registry's drug synonyms“Publication of results of competing trials SELECT2 \& Angel Aspect”
- terminated · 2023-06-06 · Life Recovery Systems · matched by the registry's drug synonyms“The study has achieved its objectives of showing feasibility, safety, and trend for improved mRS. FDA and LRS agreed that this study should be terminated, and that a new, PIVOTAL trial should be started.”
- withdrawn · 2023-03-23 · Universitaire Ziekenhuizen KU Leuven · matched by the registry's drug synonyms“organizationally not yet possible”
- withdrawn · 2023-01-18 · University of Wisconsin, Madison · matched by the registry's drug synonyms“due to COVID”
- terminated · 2022-10-12 · Wake Forest University Health Sciences · matched by the registry's drug synonyms“PI changed institution and impossible to solve problem with contract's sites”
- withdrawn · 2022-07-26 · University of Wisconsin, Madison · matched by the registry's drug synonyms“Study closed prior to opening to enrollment, due to funding availability for study”
- withdrawn · 2022-05-27 · University of Alberta · matched by the registry's drug synonyms“Could not get study started.”
- terminated · 2022-05-19 · Sir Charles Gairdner Hospital · Tissue Plasminogen Activator (tPA)“Insufficient budget for further study agents”
- terminated · 2021-12-29 · Rajaie Cardiovascular Medical and Research Center · matched by the registry's drug synonyms“Due to the COVID-19 pandemic”
- terminated · 2021-10-26 · Cedars-Sinai Medical Center · matched by the registry's drug synonyms“Identification of eligible patients was slower than anticipated.”
Paediatric incentives and obligations for FGA's drugs
For ancrod, fibrinolysin, human, plasminogen, alfimeprase: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · FGA is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names ancrod, fibrinolysin, human, plasminogen, alfimepraseRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/05/322 withdrawn 28 Oct 2005: Treatment of acute peripheral arterial occlusionRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA EU/3/05/322, 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of ancrod, fibrinolysin, human, plasminogen, alfimepraseRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of ancrod, fibrinolysin, human, plasminogen, alfimepraseRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 49 interventional studies of ancrod, fibrinolysin, human, plasminogen, alfimeprase include patients under 18; 5 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 5 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.